Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SATELITE - Salvage Therapy in Granulomatosis with Polyangiitis
2024-516687-28-00Phase 3Suspended
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of rituximab, tocilizumab, tofacitinib, methotrexate, mycophenolate mofetil and 2 more in granulomatosis with polyangiitis (GPA), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Remission or response at 12 weeks. Started Nov 2024; status: suspended.
02
Drugs
03
Conditions
granulomatosis with polyangiitis (GPA)
Beyond the preview
Go deeper on 2024-516687-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516687-28-00.